HC Wainwright Reiterates “Buy” Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $30.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 488.24% from the stock’s previous close. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2028 earnings at $1.31 EPS.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.00.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $5.10 on Tuesday. The company has a 50 day moving average price of $4.89 and a 200-day moving average price of $5.45. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $8.96. The company has a market capitalization of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million for the quarter, compared to analysts’ expectations of $85.62 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The firm’s quarterly revenue was up 34.9% on a year-over-year basis. On average, analysts forecast that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares during the last quarter. Teacher Retirement System of Texas grew its stake in BioCryst Pharmaceuticals by 4.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock worth $380,000 after buying an additional 2,519 shares during the last quarter. Fifth Third Bancorp grew its stake in BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,500 shares during the last quarter. ProShare Advisors LLC grew its stake in BioCryst Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after buying an additional 4,041 shares during the last quarter. Finally, Teza Capital Management LLC grew its stake in BioCryst Pharmaceuticals by 12.8% during the 3rd quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock worth $261,000 after buying an additional 4,180 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.